FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Dannel Yeo; Hong He; Oneel Patel; Andrew M Lowy; Graham S Baldwin; Mehrdad Nikfarjam

Journal article

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Dannel Yeo, Hong He, Oneel Patel, Andrew M Lowy, Graham S Baldwin, Mehrdad Nikfarjam

BMC Cancer | BMC | Published : 2016

DOI: 10.1186/s12885-016-2057-z

Download PDF

University of Melbourne Researchers

Graham Baldwin Author Surgery - Austin Health

Oneel Patel Author Surgery - Austin Health

Mehrdad Nikfarjam Author Surgery - Austin Health

Hong He Author Surgery - Austin Health

Related Projects (2)

Identification Of A New Target For Colon Cancer Therapy

Increased level of PAK1(a protein kinase) was associated with the progression of colorectal (large bowel) cancer (CRC). Gastrin peptides are..

Gastrins And Colorectal Cancer

My major goal for the past 20 years has been to understand how hormones such as gastrin stimulate the development of gastrointestinal cancer..

Grants

Awarded by National Health and Medical Research Council of Australia

Awarded by National Institutes of Health

Funding Acknowledgements

We thank Prof. Ian Gordon, Statistical Consulting Centre, The University of Melbourne, Parkville, Australia for his assistance with statistical analysis, and Chelsea Dumesny, Nhi Huynh, and Marie Laval for skilled assistance with the animal experiments. D.Y. is supported by Australian Rotary Health (The Ian Loxton Pancreatic Cancer Research PhD Scholarship).This work was supported by National Health and Medical Research Council of Australia Grants [508908 to H.H] and [1020983 to G.S.B]; National Institutes of Health [CA155620-01 to A.M.L]; Austin Hospital Medical Research Foundation (M.N); and Sir Edward Dunlop Foundation Grant (M.N).